baber/WOPTO huggingface dataset:
Patent CA-3079081-A1 (CA)
Inventor: BARTBERGER MICHAEL D
IPC: A61K31/50
Filed: 2018-10-18
Abstract: La présente invention concerne des inhibiteurs de l'activité de protéine de canal à potentiel de récepteur transitoire 6 (TRPC6). La présente invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, des compositions pharmaceutiques comprenant un composé selon l'invention, un procédé de production des composés selon l'invention et des utilisations thérapeutiques associées.
Patent CA-3079487-A1 (CA)
Inventor: LAHOUGUE ARNAUD
IPC: B01J35/02
Filed: 2018-10-22
Abstract: The invention relates to a method for converting a gas into methane (CH4) which includes: - a step of activating a catalytic material including praseodymium (Pr6O11) associated with nickel oxide (NiO) and alumina (Al2O3), the respective proportions of which are, relative to the total weight of these three compounds: - Pr6O11: 1 wt% to 20 wt%, - NiO: 1 wt% to 20 wt%, and - Al2O3: 60 to 98 wt%; and - a step of passing a gas including at least one carbon monoxide (CO) over the activated catalytic material.
Patent CA-3082433-A1 (CA)
Inventor: GUY GEOFFREY
IPC: A61K45/06
Filed: 2018-11-15
Abstract: La présente invention concerne l'utilisation de cannabidiol (CBD) dans le traitement de patients atteints d'un syndrome de Lennox-Gastaut (LGS) qui sont considérés comme étant des échecs de traitement sur leur médication existante. En particulier, l'utilisation de CBD a été trouvée pour réduire de manière statistiquement significative les crises de chute et la fréquence totale des crises chez des patients qui ont essayé des médicaments anti-épileptiques (AED) et en échec ou ceux qui prennent actuellement des AED, mais ont des crises non contrôlées. De préférence, les AED qui ont été présentés comme étant des défaillances de traitement sont un ou plusieurs des médicaments suivants : rufinamide, lamotrigine, topiramate et/ou felbamate. De préférence, le CBD utilisé se trouve sous forme d'extrait hautement purifié de cannabis de sorte que le CBD est présent à plus de 98% de l'extrait total (en poids) et que les autres composants de l'extrait sont caractérisés. En particulier, le cannabinoïde tétrahydrocannabinol (THC) a été sensiblement retiré, jusqu'à un niveau qui n'est pas supérieur à 0,15 % (en poids) et l'analogue propyle du CBD, la cannabidivarine (CBDV), est présente dans des teneurs pouvant atteindre 1%. En variante, le CBD peut être un CBD produit synthétiquement.
Patent CA-3084162-A1 (CA)
Inventor: STEWARD JOHN BRIAN
IPC: A01L3/00
Filed: 2018-12-03
Abstract: L'invention concerne des kits de soins des sabots appropriés pour traiter le sabot d'un animal. L'invention concerne également des procédés de fabrication et d'utilisation desdits kits de soins des sabots.
Patent CA-3084319-A1 (CA)
Title: Compositions, procedes, kits et systemes pour le traitement du cancer et la therapie d'intervention metabolique
Inventor: LI XIYAN
IPC: A61K31/715
Filed: 2018-12-11
Abstract: La présente invention concerne des compositions et des procédés de traitement du cancer au moyen de régimes alimentaires à modification nutritionnelle et/ou de traitement par dialyse, par exemple par diminution d'acides aminés pour un ou plusieurs acides aminés non essentiels. Dans certains aspects, la présente invention concerne des compositions et des procédés de traitement de l'obésité avec de tels régimes alimentaires modifiés et/ou un tel traitement par dialyse. En outre, dans certains aspects, la présente invention concerne des compositions et des procédés pour traiter une maladie rénale avec de tels régimes alimentaires modifiés et/ou un tel traitement par dialyse.
Patent CA-3086491-A1 (CA)
Title: Serre
Inventor: NOWE WILLE
IPC: A01G9/24
Filed: 2018-12-21
Abstract: La présente invention concerne une serre (1) constituée d'une poutre faîtière (4) s'étendant sur une certaine distance au-dessus de son toit (5) définissant deux zones latérales allongées (6, 7) sur l'un ou l'autre côté de la poutre faîtière (4). La poutre faîtière (4) est composée d'un ou plusieurs espaces creux allongés (8) et d'une ou plusieurs ouvertures pouvant être fermées (9) dans les deux zones latérales (6, 7). Les ouvertures (9) relient fluidiquement l'extérieur (10) de la serre (1) avec son intérieur (13) et peuvent être fermées à une extrémité et ouvertes à leur autre extrémité en fonction du sens du vent.
Patent CA-3090238-A1 (CA)
Inventor: COSCARELLA GABE
IPC: E03F7/04
Filed: 2020-08-17
Abstract: A backwater valve has a hollow valve body having an inlet and an outlet, and a valve member pivotally movable about a pivot axis disposed above the inlet. The valve member pivots between an open position in which the valve member is away from the inlet and a closed position in which the valve member closes the inlet. A cam is rotatably mounted above the inlet. The cam has a first rotary position in which the valve member is permitted to move to the open position and a second rotary position in which the cam engages the valve member to secure the valve member in the closed position. With the valve member in the open position, the cam pushes the valve member toward the close position as the cam moves toward the second rotary position.
Patent CA-3090474-A1 (CA)
Title: Modified urea-formaldehyde binders for non-woven fiber glass mats
Inventor: ZHENG GUODONG
IPC: C03C27/10
Filed: 2020-08-11
Abstract: A method of forming a binder composition includes providing a urea-formaldehyde resin and combining one or more starch compounds with the urea-formaldehyde resin to form a starch modified urea-formaldehyde resin. The one or more starch compounds may be combined with the urea-formaldehyde resin so that the starch modified urea-formaldehyde resin includes about 1 wt.% to about 10 wt.% of the one or more starch compounds.
Patent CA-3091827-A1 (CA)
Title: Administration of tasimelteon under fasted conditions
Inventor: DRESSMAN MARLENE MICHELLE
IPC: A61K31/343
Filed: 2015-01-07
Abstract: ABSTRACT One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least 1/2 hour prior to administration, no food at least 1 hour prior to administration, no food at least 1-1/2 hours prior to administration, no food at least 2 hours prior to administration, no food at least 2-1/2 hours prior to administration, or no food at least 3 hours prior to administration.  According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder. Date Recue/Date Received 2020-09-01
Patent CA-3094959-A1 (CA)
Inventor: CANDEL BRUNO M B
IPC: E01B9/18
Filed: 2019-02-12
Abstract: An anchoring assembly (40) for fastening a railway rail (13) to an underlying foundation (16), comprising:  a base plate (12) configured to receive the rail (13);  a fastener (30) configured to fasten the base plate (12) to the underlying foundation (16); and  a rigid sleeve (50) defining a passage (52) through which a stem (32) of the fastener (30) passes,  wherein the base plate (12) comprises an opening and the sleeve (50) is configured to extend through the base plate opening,  wherein the sleeve (50) extends a distance greater than a thickness of the base plate (12) such that the sleeve extends from a top surface of the base plate (12) and beyond a bottom surface of the base plate when installed, and  wherein the sleeve (50) is configured such that a compressive load applied by the fastener (30) when installed is transmitted through the sleeve (50) to the underlying foundation (16).
Patent CA-3095186-A1 (CA)
Title: Stable anti-cd79b immunoconjugate formulations
Inventor: PATEL ANKIT R
IPC: A61P35/00
Filed: 2019-04-12
Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
Patent CA-3095970-A1 (CA)
Title: Combinaison d'un cannabinoide et d'un agent chimiotherapeutique pour le traitement du cancer du sein
Inventor: LIU WAI
IPC: A61K31/337
Filed: 2019-04-04
Abstract: La présente invention dans le domaine de la thérapie du cancer est basée sur la découverte (illustrée en Figure 4) que lorsque des cannabinoïdes sont administrés à des cellules cancéreuses après qu'un agent chimiothérapeutique a été administré, le traitement combiné conduit à une viabilité réduite des cellules cancéreuses par rapport à l'administration de l'agent chimiothérapeutique seul. L'invention concerne une composition pharmaceutique comprenant un agent chimiothérapeutique à utiliser dans le traitement du cancer du sein, ledit traitement comprenant une première phase dans laquelle l'agent chimiothérapeutique est administré, et une seconde phase ultérieure dans laquelle un cannabinoïde est administré.
Patent CA-3095972-A1 (CA)
Title: Core/shell-vacancy engineering (csve) of catalysts for electrochemical co2 reduction
Inventor: SARGENT EDWARD
IPC: C25B3/25
Filed: 2019-05-08
Abstract: The invention relates to a catalyst system for electrocatalyzing conversion of CO2 into multi-carbon hydrocarbons and/or alcohols, and to the method to produce it. The catalyst comprises a core-shell structure comprising a core that is composed of metal sulphide and a shell that is composed of a metal with vacancies.
Patent CA-3097422-A1 (CA)
Title: Cartridge, and electrophotographic image forming apparatus which uses cartridge
Inventor: MIYABE SHIGEO
IPC: G03G15/06
Filed: 2009-06-09
Abstract: A cartridge for an electrophotographic image forming apparatus. The cartridge includes a casing; a developing roller rotatably supported in the casing to permit rotation about its axis; a photosensitive drum rotatably supported in the casing to permit rotation about its axis; a first coupling member including (i) a first end portion operatively connected to the developing roller, (ii) a second end portion, and (iii) a connecting portion connecting the two end portions; and a second coupling member including a projection, wherein the first coupling member is movable between a first position in which its axis is substantially parallel to the roller axis, and a second position in which its axis is inclined with respect to the roller axis, and wherein the maximum angle of inclination of the axis of the first coupling member with respect to the roller axis is between 20 to 60 degrees.
Patent CA-3098278-A1 (CA)
Inventor: ROSSIGNOLI FILIPPO
IPC: A61K35/28
Filed: 2019-04-24
Abstract: L'invention concerne un procédé de production de particules cellulaires ayant une activité antitumorale, qui consiste à isoler la particule cellulaire provenant d'une population de cellules avec un phénotype qui peut être attribué à des péricytes dérivés de tissu adipeux humain (AD-PC) qui expriment la cytokine TRAIL antitumorale.
Patent CA-3101015-A1 (CA)
Inventor: MCCALL MICHAEL JAY
IPC: B02C18/16
Filed: 2019-05-23
Abstract: A shredder includes a shredder box having first and second opposite end walls, and first and second opposite side walls that extend between the first and second end walls. The shredder further includes a shredder rotor positioned within an interior of the shredder box, an access door that is pivotally moveable, and a control system for monitoring various parameters to operate the shredder. A side access region is defined between the first and second end walls when the access door is in the open position. The side access region provides access to the shredder rotor and includes an open region defined between the first and second end walls at the second side of the shredder. The open region has an open top which is free of obstructions extending between the first and second end walls.
Patent CA-3101742-A1 (CA)
Inventor: ROBOTHAM MARTIN PAUL
IPC: G10K9/122
Filed: 2019-05-16
Abstract: A notification appliance is disclosed and includes a sound engine that generates sound according to an acoustic pattern and the power control that regulates input voltage to the sound engine that is matched to the acoustic pattern. A method of powering a sounder is also disclosed and includes providing a constant input current and regulating an input voltage to a phase of a sound engine corresponding with an acoustic signal generated by a sound engine.
Patent CA-3102601-A1 (CA)
Title: Methods for detecting antiviral-drug resistant virus
Inventor: MBISA JEAN LUTAMYO
IPC: C12Q1/70
Filed: 2019-06-04
Abstract: The present invention is directed to a method for detecting the presence or absence of an antiviral drug-resistant HSV, comprising: (a) identifying one or more HSV mutation selected from:(i) a thymidine kinase (TK) mutation selected from 250G>A (HSV-2),0C>T (HSV-1), 268C>T (HSV-2), 373C>T (HSV-1), 146T>G (HSV-1), 363G>A (HSV-), 497T>A (HSV-1), 558G>T (HSV-2), 641A>G (HSV-2), 715T>C (HSV-1), 938T>C(HSV-2), 437_438insA (HSV-1), 169delC (HSV-1), 170delC (HSV-1), 171delC (HSV-1), 1072delC (HSV-1), 458delC (HSV-2), 459delC (HSV-2), 460delC (HSV-2), 461delC (HSV-2), 881delC (HSV-1), 882delC (HSV-1), 883delC (HSV-1), 884delC (HSV-1), and 885delC (HSV-1); and(ii) a DNA polymerase (DNA pol) mutation selected from 1882C>G(HSV-2), 2405T>G (HSV-1), 2500G>T (HSV-1), 2515A>G (HSV-1), 2892_2893insT(HSV-1), 2893_2894insT (HSV-1), 2894_2895insT (HSV-1), and 2895_2896insT (HSV-1);wherein the presence of said one or more HSV mutation confirms the presence of an antiviral drug-resistant HSV, and wherein the absence of said one or more HSV mutation is indicative of the absence of an antiviral drug-resistant HSV.
Patent CA-3103966-A1 (CA)
Inventor: HOFF MARK
IPC: B32B3/00
Filed: 2019-06-19
Abstract: This disclosure includes ice packs (10) that comprise paper and absorbent material (22A, 22), and also includes various methods of adding liquid to, freezing, shipping, and/or using such ice packs (10). Some of the ice packs (10) of this disclosure have a body (14) that includes first and second layers (54, 58) of paper and one or more side panels (66A) coupled thereto such that the body (14) is expandable. The absorbent material (22A, 22) of some of the ice packs (10) of this disclosure comprises a laminate having an inner layer (70A, 70B, 70C, 70) of superabsorbent polymer disposed between first and second outer layers (78), where the first outer layer (74) comprises tissue and the second outer layer (78) comprises at least one of a tissue and a carded nonwoven.
Patent CA-3104218-A1 (CA)
Title: Cancer therapy
Inventor: MARTYN GLEN
IPC: A61P35/04
Filed: 2019-06-25
Abstract: A non-viable, whole-cell Mycobacterium for use in the treatment, reduction, inhibition or control of one or more tumours in a checkpoint inhibitor refractory patient, wherein said checkpoint inhibitor refractory patient is intended to undergo checkpoint inhibition therapy simultaneously, separately or sequentially with administration of the Mycobacterium, and/or co-stimulatory checkpoint therapy, and optionally further comprising administering one or more additional anticancer treatments or agents.
Patent CA-3105990-A1 (CA)
Inventor: OTTENHALL ANNA
IPC: C02F1/28
Filed: 2019-07-12
Abstract: The present invention relates to a composition and method for recovery and/or bioremediation of oil spills and/or hydrophobic hydrocarbons, the composition comprising: (a) cellulosic material, (b) a charged polymer adsorbed to said cellulosic material, and optionally (c) microorganisms combined with said polymer and/or cellulosic material.
Patent CA-3106574-A1 (CA)
Title: Vaccins a base de arid1a, cdkn2a, kmt2b, kmt2d, tp53 et pten contre le cancer
Inventor: PLASTERK RONALD HANS ANTON
IPC: G01N33/574
Filed: 2019-07-25
Abstract: La présente invention concerne le domaine des cancers. L'invention concerne particulièrement le domaine des approches orientées vers le système immunitaire pour la réduction de tumeurs et la lutte contre ces dernières. Certains aspects de l'invention concernent des vaccins, des vaccinations et d'autres moyens de stimulation d'une réponse immunitaire spécifique à un antigène contre une tumeur chez des individus. Ces vaccins comprennent des néo-antigènes obtenus à partir de mutations du cadre de lecture qui ont pour conséquence des séquences hors cadre des gènes ARID1A, CDKN2A, KMT2B, KMT2D, TP53 et PTEN dans le cadre. Ces vaccins sont également utiles pour une utilisation standard.
Patent CA-3108178-A1 (CA)
Title: Connection and features for interchangeable nosecone for a trolling motor
Inventor: BURTON AARON J
IPC: B63H21/36
Filed: 2018-03-28
Abstract: ABS TRACT Various implementations described herein are directed to a trolling motor including an electric motor having a propeller coupled thereto, a shaft configured for coupling the electric motor to a watercraft. The shaft is configured to rotate relative to the watercraft and the shaft defines an internal passage. The trolling motor also includes a housing that encapsulates the motor, a removable nosecone operably coupled to the housing opposite the propeller and configured to encapsulate at least one marine device. One or more mechanical connection features are provided to enable removable connection of the nosecone to the remainder of the trolling motor housing. The mechanical connection feature comprises a bolt receiver. The nosecone comprises a retention bolt including a bolt head or retention nut. The retention bolt is configured to engage the bolt receiver and apply retention force to the removable nosecone in response to tightening of the retention bolt. Date Recue/Date Received 2021-02-05
Patent CA-3113127-A1 (CA)
Title: Concrete structure manufacturing apparatus and method
Inventor: PETIT AGNES
IPC: B28B1/00
Filed: 2019-06-24
Abstract: The present relates to an apparatus for manufacturing 3-dimensional concrete structures comprising a projection head (1) for spraying concrete material, wherein the projection head (1) comprises a projection nozzle (11) for spraying the concrete material and at least two guiding surfaces (12) provided on both sides of the projection nozzle (11) and defining a volume in between, such that the projection nozzle (11) is adapted to spray the concrete material into said volume, and wherein the projection head (1) is repeatedly moved along a predefined path by a control means and is configured to adjust the position of the two guiding surfaces (12) during the movement of the projection nozzle (11) so as to create a 3-dimensional concrete structure made of a plurality of projected concrete layers.
Patent CA-3118035-A1 (CA)
Inventor: ZEMLA ANDREAS ROBERT
IPC: F42C9/14
Filed: 2019-10-28
Abstract: A system and a method of providing a reliable and consistent time delay in an oil and gas exploration/recovery device inserted in a bore hole is presented. The reliability and consistency of the time delay is a result of the use of electronic circuitry in determining the length of time delay. The system and method presented provide a time delay unit that is modular/commoditized, facilitating quick and easy integration of each component of the time delay unit in the field. Further, assembly and disassembly of the time delay unit is easily accomplished in the field and may be designed to operate with standard percussion and detonation elements. As such, it is possible to ship the time delay unit without any percussion or detonation elements and these energetic elements may be easily added to the unit immediately prior to use. Such an arrangement greatly reduces or eliminates any safety protocols or restrictions required when shipping or handling energetic materials such as percussion or detonator elements.
Patent CA-3118537-A1 (CA)
Inventor: FOSTER DONALD
IPC: C12N15/09
Filed: 2019-11-05
Abstract: Un aspect de la présente invention concerne un agent ARN double brin (ARNdb) pouvant inhiber l'expression d'un gène cible. D'autres modes de réalisation de l'invention concernent des compositions pharmaceutiques comprenant lesdites molécules d'ARNdb adaptées à un usage thérapeutique, et des méthodes d'inhibition de l'expression d'un gène cible par l'administration de ces molécules d'ARNdb, par exemple, pour le traitement de divers états pathologiques.
Patent CA-3121034-A1 (CA)
Title: Firing head and method of utilizing a firing head
Inventor: BRADY THOMAS RYAN
IPC: E21B43/1185
Filed: 2019-11-27
Abstract: A firing head assembly may include a tubular housing; a valve slidably disposed within the tubular housing; a lock mandrel disposed in the tubular housing between the valve and the tubular housing second end; a firing pin holder disposed in the tubular housing between the lock mandrel and the tubular housing second end; an engagement mechanism operably contacting the lock mandrel and the firing pin holder latch. The valve may have a piston end exposed to the lumen. The lock mandrel may be restrained from axial movement by a shear element. The firing pin holder may include a firing pin and latch. The engagement mechanism may be switchable between an engaged arrangement and a disengaged arrangement. The engagement mechanism may be configured to transition from the engaged arrangement to the disengaged arrangement in response to an axial movement of the lock mandrel.
Patent CA-3122123-A1 (CA)
Title: Non-oriented electrical steel sheet
Inventor: ODA YOSHIHIKO
IPC: C22C38/02
Filed: 2019-12-10
Abstract: Proposed is a non-oriented electrical steel sheet being low in iron loss and excellent in tensile strength and fatigue strength, which has a chemical composition comprising C: not more than 0.005 mass%, Si: 3 to 5 mass%, Mn: not more than 5 mass%, P: not more than 0.1 mass%, S: not more than 0.01 mass%, Al: not more than 3 mass%, N: not more than 0.005 mass%, Zn: 0.0005 mass% to 0.003 mass%, and the remainder being Fe and inevitable impurities, an average crystal grain size being not more than 40 pm, the number of the inclusions having a diameter of not less than 5pm being not more than 5/mm2, a tensile strength being not less than 600 MPa, and the fatigue strength being not less than 450 MPa.
Patent CA-3122348-A1 (CA)
Title: Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
Inventor: CUMMINGS W JASON
IPC: A61K39/395
Filed: 2017-07-31
Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
Patent CA-3122435-A1 (CA)
Title: Perforating gun with switch cartridge
Inventor: LAGRANGE TIMOTHY E
IPC: E21B43/1185
Filed: 2019-12-20
Abstract: An apparatus for selectively firing a perforating gun having a plurality of gun assemblies includes a plurality of cartridge assemblies. Each cartridge assembly is associated with a gun assembly of the plurality of gun assemblies. Each cartridge assembly includes a body having a cavity, an input contact configured to receive a signal, and a throughput contact configured to convey the signal. The perforating gun may include a carrier and at least one bulkhead.